Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00737672 · ClinicalTrials.gov registry record · Phase 3
GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis
A Phase 3 study, sponsored by W.L.Gore & Associates.
- Completed
- Registry status
- Phase 3
- Development phase
- 293
- Enrollment target
NCT00737672 is a Phase 3 study that has completed, run by W.L.Gore & Associates. The registered enrollment target is 293 participants.
The verdict
NCT00737672, a Phase 3 study, has completed, sponsored by W.L.Gore & Associates.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 293 participants
- Enrollment target
Study Summary
The objective of the study is to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface when used to revise arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis.
Interventions
- PROCEDURE Percutaneous Transluminal Angioplasty
- DEVICE GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 293 participants |
| Start Date | 2008-09 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00737672
The ClinicalTrials.gov registry entry for NCT00737672 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 293 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is W.L.Gore & Associates, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Percutaneous Transluminal Angioplasty is the first listed.
NCT00737672 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00737672 about?
NCT00737672 is a clinical study titled "GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis". The objective of the study is to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface when used to revise arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis.
What is the current status of trial NCT00737672?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 293 participants. The study started on 2008-09. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00737672?
The interventions under investigation include: Percutaneous Transluminal Angioplasty (PROCEDURE), GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface (DEVICE).
Who is sponsoring clinical trial NCT00737672?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.